Virology News and Research

Latest Virology News and Research

GLOBVAC programme tests new vaccine that may provide complete protection against Ebola virus

The Research Council of Norway's Programme for Global Health and Vaccination Research (GLOBVAC) is co-funding testing of a new vaccine against Ebola that is drawing widespread international attention. The research programme has allocated NOK 20 million towards this work.

11 Aug 2015

Researchers apply new approach to make improved nasal spray flu vaccine

Johns Hopkins Bloomberg School of Public Health researchers say they have developed a method that could make a nasal spray flu vaccine effective for those under two and over 49 - two groups for which the vaccine is not approved.

11 Aug 2015

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

Dasabuvir (trade name Exviera) and the fixed-dose drug combination ombitasvir/paritaprevir/ritonavir (trade name Viekirax) have been available since January 2015 for the treatment of adults with chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care had examined their added benefit in a dossier assessment completed in April 2015.

7 Aug 2015

Experimental Ebola virus vaccine protects cynomolgus macaques against current EBOV outbreak strain

National Institutes of Health scientists report that a single dose of an experimental Ebola virus (EBOV) vaccine completely protects cynomolgus macaques against the current EBOV outbreak strain, EBOV-Makona, when given at least seven days before exposure, and partially protects them if given three days prior.

7 Aug 2015

Urban emergency department sees high rates of HCV infection among intravenous drug users, Baby Boomers

An urban emergency department that set up a hepatitis C testing protocol saw high rates of infection among intravenous drug users and Baby Boomers, with three-quarters of those testing positive unaware they were infected.

7 Aug 2015

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Antiva Biosciences, Inc. (formerly Hera Therapeutics), a biopharmaceutical company developing antiviral therapeutics, today announced that it has raised $16 million in a Series B financing, its first institutional round.

6 Aug 2015

Children increase parents’ risk for viral infection

The BIG LoVE (Utah Better Identification of Germs-Longitudinal Viral Epidemiology) study, led by scientists at the University of Utah School of Medicine, finds that each bundle of joy puts the entire household at increased risk for infection with viruses that cause colds, flu, and other respiratory illnesses.

5 Aug 2015

University of Liverpool study finds that HIV can continue to grow in patients despite treatment

HIV can continue to grow in patients who are thought to be responding well to treatment, according to research by the University of Liverpool.

5 Aug 2015

New study reveals how infectious proteins spread from gut to the brain

Diagnosis of deadly brain conditions could be helped by new research that shows how infectious proteins that cause the disease spread.

5 Aug 2015

IP10 levels linked to HBsAg decline during TDF treatment

Baseline serum interferon-inducible protein 10 levels predict hepatitis B surface antigen reduction in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection treated with tenofovir disoproxil fumarate, findings indicate.

4 Aug 2015

Baseline HBsAg, platelet count predict spontaneous HBsAg seroclearance

Hepatitis B surface antigen level and platelet count at baseline are significantly associated with spontaneous HBsAg seroclearance in hepatitis B virus carriers and those with chronic infection, research suggests.

4 Aug 2015

Genotype A HBV mapped in acute, chronic Japanese patients

Not only is genotype A the most common genotype among Japanese patients with acute hepatitis B virus infection, but its prevalence is spreading among young adults with chronic HBV infection, shows a nationwide study.

4 Aug 2015

Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Northwestern Medicine scientists have received a five-year, $17.5 million grant from the National Institutes of Health for an interdisciplinary project that aims to invent, develop and test an implantable drug delivery system to protect high-risk individuals from HIV infection for up to a year at a time.

4 Aug 2015

Penn Medicine devises new approach to develop vaccines against lethal diseases

Researchers at the Perelman School of Medicine at the University of Pennsylvania have devised an entirely new approach to vaccines - creating immunity without vaccination.

4 Aug 2015

Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

A vaccine containing virus-like nanoparticles, or microscopic, genetically engineered particles, is an effective treatment for respiratory syncytial virus (RSV), according to researchers at Georgia State University.

4 Aug 2015

First biodegradable gene delivery system efficiently penetrates human airway mucus barrier of lung tissue

Researchers at the Johns Hopkins University School of Medicine, Johns Hopkins University Department of Chemical and Biomolecular Engineering, and Federal University of Rio de Janeiro in Brazil have designed a DNA-loaded nanoparticle that can pass through the mucus barrier covering conducting airways of lung tissue — proving the concept, they say, that therapeutic genes may one day be delivered directly to the lungs to the levels sufficient to treat cystic fibrosis (CF), chronic obstructive pulmonary disease, asthma and other life-threatening lung diseases.

4 Aug 2015

Shire acquires Foresight Biotherapeutics for $300 million

Shire plc announced today that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million.

3 Aug 2015

RNA-binding protein ROQUIN regulates response to DNA damage

Messenger (mRNA) molecules are a key component of protein biosynthesis. They are first transcribed as a "working copy" of the DNA and then translated into protein molecules.

3 Aug 2015

First large field trial shows VSV-ZEBOV is effective against Ebola

A vaccine against the Ebola virus, tested in West Africa for the first time in a field trial, has proved to be effective. People who had come into close contact with someone recently infected, and who are therefore at particularly high risk, were vaccinated.

3 Aug 2015

Tests show VSV-ZEBOV vaccine safe and effective against Ebola

Tests of the experimental Ebola vaccine VSV-ZEBOV in over 7500 participants in Guinea suggest that the vaccine provides high protection against the disease as early as ten days after vaccination, in adults who have potentially been exposed to the virus by coming in close contact with a recently infected person.

31 Jul 2015

Virology News and Research

Latest Virology News and Research

GLOBVAC programme tests new vaccine that may provide complete protection against Ebola virus

Researchers apply new approach to make improved nasal spray flu vaccine

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

Experimental Ebola virus vaccine protects cynomolgus macaques against current EBOV outbreak strain

Urban emergency department sees high rates of HCV infection among intravenous drug users, Baby Boomers

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Children increase parents’ risk for viral infection

University of Liverpool study finds that HIV can continue to grow in patients despite treatment

New study reveals how infectious proteins spread from gut to the brain

IP10 levels linked to HBsAg decline during TDF treatment

Baseline HBsAg, platelet count predict spontaneous HBsAg seroclearance

Genotype A HBV mapped in acute, chronic Japanese patients

Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Penn Medicine devises new approach to develop vaccines against lethal diseases

Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

First biodegradable gene delivery system efficiently penetrates human airway mucus barrier of lung tissue

Shire acquires Foresight Biotherapeutics for $300 million

RNA-binding protein ROQUIN regulates response to DNA damage

First large field trial shows VSV-ZEBOV is effective against Ebola

Tests show VSV-ZEBOV vaccine safe and effective against Ebola

Microplate-based assays in virology research eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging